Literature DB >> 22210097

Therapeutic drug monitoring of voriconazole in children.

Jennifer Chen1, Carol Chan, David Colantonio, Winnie Seto.   

Abstract

Voriconazole is an extended-spectrum triazole antifungal with activity against a wide variety of pathogens, including Aspergillus, Candida, Cryptococcus neoformans, Fusarium, and Scedosporium. It exerts its antifungal activity by blocking the synthesis of fungal cell membranes and is considered the first-line treatment for invasive aspergillosis. Because the pharmacokinetics of voriconazole can demonstrate considerable variability, it has been suggested that monitoring plasma levels of voriconazole may play an important role in optimizing the efficacy and safety of the drug in complex patients like those at risk of or who have invasive aspergillosis. In this article, we review the criteria for therapeutic drug monitoring and assess the evidence for using plasma voriconazole concentrations to individualize doses in children.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22210097     DOI: 10.1097/FTD.0b013e31823f3516

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

1.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

2.  Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children.

Authors:  Sarah Allegra; Giovanna Fatiguso; Silvia De Francia; Fabio Favata; Elisa Pirro; Chiara Carcieri; Amedeo De Nicolò; Jessica Cusato; Giovanni Di Perri; Antonio D'Avolio
Journal:  Br J Clin Pharmacol       Date:  2017-09-24       Impact factor: 4.335

Review 3.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

4.  Voriconazole monitoring in children with invasive fungal infections.

Authors:  Lyn Tucker; Tara Higgins; Eric F Egelund; Baiming Zou; Vini Vijayan; Charles A Peloquin
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jan-Feb

5.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

6.  In vitro study of the variable effects of proton pump inhibitors on voriconazole.

Authors:  Krista L Niece; Natalie K Boyd; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 7.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

8.  Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.

Authors:  Takuto Takahashi; Angela R Smith; Pamala A Jacobson; James Fisher; Nathan T Rubin; Mark N Kirstein
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

9.  Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy.

Authors:  Sviatlana L Kandaurava; Kseniya S Baslyk; Alexandr A Migas; Anna V Hill; Oleg I Bydanov; Volha A Mishkova; Olga V Aleinikova
Journal:  Curr Med Mycol       Date:  2020-12

10.  Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.

Authors:  Helen Y Chu; Rupali Jain; Hu Xie; Paul Pottinger; David N Fredricks
Journal:  BMC Infect Dis       Date:  2013-02-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.